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variceal rebleeds
Abstract
Background: Esophageal and gastric varices are a frequent complication of patients with increased portal
venous pressure. Gastic varice occurs and bleeds less frequently than esophageal varice in patients with portal
hypertension. Bleeding of gastric varices, however, tends to be more severe and is associated with a higher rate
of rebleeds and mortality. Currently, the treatment for preventing secondary gastric variceal hemorrhage
includes transjuglar intrahepatic portosystemic shunting, band ligation propranolol and isosorbide
mononitrate. Cyanoacrylate is the preferred treatment and has been effective in the treatment of actue gastric
variceal hemorrhage worldwide but its use is limited in the United States. The use of cyanoacrylate in the
preventing secondary gastric varices has not been well studied. It has been well documented that beta-
blockers are effective in decreasing the incidence of secondary esophageal varices and is used empirically in
prophylaxis of secondary gastric varices, without proof. The purpose of this systematic review is to determine
whether the use of cyanoacrylate more effective than beta-blockers in preventing secondary gastric varices?
Methods: An exhaustive search was conducted using Medline-OVID, CINAHL, EBMR Multifile, and Web of
Science using the keywords: cyanoacrylate, beta-blocker, gastric varices and portal hypertension. Relevant
articles were assessed for quality using GRADE. A search on the NIH clinical trials site reveals there are no
trials comparing the efficacy of cyanoacrylate and beta-blockers in preventing secondary gastric varices.
Results: Two studies met the inclusion criteria and were included in this systematic review. A randomized
controlled trial included 64 patients with portal hypertension and upper gastrointestinal bleeding who met
the inclusion criteria. The study showed a statistically significant reduction in secondary gastric variceal
hemorrhage with cyanoacrylate injection compared beta-blocker. A randomized control trial consisting of 41
patients with esophageal or gastric variceal bleeding were included in the study. Results demonstrated that
repeat cyanoacrylate injections were associated with more complication compared to beta-blocker with
similar rebleeding rates after 6 weeks.
Conclusion: Cyanoacrylate is effective in decreasing the incidence of gastroesphageal varice type II and
isolated gastric varice type I rebleeds and mortality compared to beta-blockers. Beta-blockers demonstated a
reduction in hepatic venous pressure gradient but there is no evidence that it prevents rebleeds from gastric
varices. In addition, mixing cyanoacrylate and lipiodol resulted in more complication than cyanoacrylate
alone. A strong recommendation can be made for the use of cyanoacrylate in both acute gastric variceal
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Abstract   
 
Background: Esophageal and gastric varices are a frequent complication of patients with 
increased portal venous pressure.  Gastic varice occurs and bleeds less frequently than 
esophageal varice in patients with portal hypertension.  Bleeding of gastric varices, 
however, tends to be more severe and is associated with a higher rate of rebleeds and 
mortality.  Currently, the treatment for preventing secondary gastric variceal hemorrhage 
includes transjuglar intrahepatic portosystemic shunting, band ligation propranolol and 
isosorbide mononitrate.  Cyanoacrylate is the preferred treatment and has been effective 
in the treatment of actue gastric variceal hemorrhage worldwide but its use is limited in 
the United States.  The use of cyanoacrylate in the preventing secondary gastric varices 
has not been well studied.  It has been well documented that beta-blockers are effective in 
decreasing the incidence of secondary esophageal varices and is used empirically in 
prophylaxis of secondary gastric varices, without proof.  The purpose of this systematic 
review is to determine whether the use of cyanoacrylate more effective than beta-blockers 
in preventing secondary gastric varices? 
 
Methods: An exhaustive search was conducted using Medline-OVID, CINAHL, EBMR 
Multifile, and Web of Science using the keywords: cyanoacrylate, beta-blocker, gastric 
varices and portal hypertension.  Relevant articles were assessed for quality using 
GRADE.  A search on the NIH clinical trials site reveals there are no trials comparing the 
efficacy of cyanoacrylate and beta-blockers in preventing secondary gastric varices. 
 
 
Results: Two studies met the inclusion criteria and were included in this systematic 
review.  A randomized controlled trial included 64 patients with portal hypertension and 
upper gastrointestinal bleeding who met the inclusion criteria.  The study showed a 
statistically significant reduction in secondary gastric variceal hemorrhage with 
cyanoacrylate injection compared beta-blocker.  A randomized control trial consisting of 
41 patients with esophageal or gastric variceal bleeding were included in the study.  
Results demonstrated that repeat cyanoacrylate injections were associated with more 
complication compared to beta-blocker with similar rebleeding rates after 6 weeks. 
 
Conclusion: Cyanoacrylate is effective in decreasing the incidence of gastroesphageal 
varice type II and isolated gastric varice type I rebleeds and mortality compared to beta-
blockers.  Beta-blockers demonstated a reduction in hepatic venous pressure gradient but 
there is no evidence that it prevents rebleeds from gastric varices.  In addition, mixing 
cyanoacrylate and lipiodol resulted in more complication than cyanoacrylate alone.  A 
strong recommendation can be made for the use of cyanoacrylate in both acute gastric 
variceal hemorrhage and secondary prophylaxis of gastric variceal bleed. 
 
Keywords:  Cyanoacrylate, beta-blocker, gastric varices, portal hypertension 
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Comparison: the efficacy of cyanoacrylate and beta-blocker in preventing gastric variceal rebleeds 
BACKGROUND 
Gastric and esophageal varices are complications of increased portal venous 
pressure.  Gastric varices occur in about 20-25% of patients with portal hypertension.1,2  
Bleeding from gastric varices occur less frequently than esophageal varices1; however, 
the bleed tends to be more severe and is associated with a higher rate of mortality.1,3,4  
Furthermore, gastric varices have a higher rate of rebleeds, occurring about 34-89% 
after control of acute hemorrhage.3,5,6   
The location of the gastric varices plays an important factor in the frequency and 
severity of bleeding.5  Gastric varices are commonly classified by location using the Sarin 
classification.  According to the classification system, there are four types of gastric 
varices: gastroesophageal varices type 1 (GOV1) are continuous with esophageal varices 
and extend 2 to 5 cm below the gastroesophageal junction; gastroesophageal varices 
type 2 (GOV2) are continuous with esophageal varices and extend into the cardia and 
fundus of the stomach; isolated gastric varices type 1 (IGV1)are varices that occur in the 
fundus of the stomach in the absence of esophageal varices; varices that occur in the 
gastric body, antrum or pylorus are called isolated gastric varices type 2 (IGV2).1,2   
The treatment of gastric varices includes controlling the active bleeding and 
preventing secondary variceal hemorrhage.  Currently, there are a number of treatment 
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options to control hemorrhaging but no standard approach has been agreed upon.  
Beta-blockers are effective in decreasing variceal pressure and esophageal varices in 
patients with portal hypertension.10  Due to this, beta-blockers have been 
recommended empirically and used without evidence.11  The use of beta-blockers in the 
treatment of gastric varices are not well studied.  Early research has indicated that beta-
blocker therapy alone or adjunctively does not improve rebleeding rates of gastric 
varices.11,15 
The use of cyanoacrylate, another treatment option, is limited in the United 
States despite promising reports.  International studies has demonstrated that 
cyanoacrylate therapy is safe and effective therapy in stabilizing acute hemorrhage.8,14  
In treating with cyanoacrylate, the hemorrhage is first visualized by an endoscope.  
Cyanoacrylate is then injected into the varix.  Once the cyanoacrylate comes in contact 
with blood, an exothermic chain polymerization reaction occurs.  Cyanoacrylate 
transforms from its original liquid form into a solid material, which physically occludes 
the vessels. 8,14  In laboratory setting, cyanoacrylate solidifies in 5-12 seconds after 
contact with human blood. 8,11  This transformation can be delayed with the use of 
lipiodol, a substances commonly used when treating gastric varices.  This property 
allows the cyanoacrylate to be injected into the varix with ease.  Lipiodol is also a 
radiopague contrast, which provides a non-invasive method to visualize the varix post-
operatively. 8   
There is a low incidence of complications from cyanoacrylate therapy which 
includes sepsis, distant embolism, gastric ulcer, mesentery hematoma, 
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hemoperitoneum and abdominal infection.7  Currently, the use of cyanoacrylate is 
limited to a number of centers in the United States under research protocol and is not 
approved by the Food and Drug Administration.9  This review will investigate and 
compare the efficacy between cyanoacrylate and beta-blockers in the prophylaxis of 
secondary gastric variceal bleeds.   
 
METHODS 
A thorough search of available medical literature was conducted using Medline-
OVID, CINAHL, EBMR Multifile, and Web of Science using the keywords: cyanoacrylate, 
beta-blocker, gastric varices and portal hypertension.  The search was refined to include 
only human articles.  The references of the articles were further searched for relevant 
sources.  Articles with primary data comparing the efficacy of cyanoacrylate and beta-
blocker in the treatment of gastric varices were included.  Relevant articles were 
assessed for quality using the Grading of Recommendations, Assessment, Development 
and Evaluation (GRADE).12  A search on the NIH clinical trials site reveals there are no 




The initial results of the search yielded seven articles for review.  Of these seven, 
two randomized controlled trials met the inclusion criteria.11,13 
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Mirsha et al study 
This randomized controlled trial11 investigated and compared the efficacy of 
beta-blocker and cyanoacrylate injection in the prevention of secondary gastric variceal 
bleeding.  The study enrolled patients with gastric varices secondary to cirrhosis from 
August 2006 to March 2009.  A total of 67 patients were enrolled, of which 64 
participated and were randomized to receive either cyanoacrylate injection or beta-
blocker.  Patients who presented with active bleeds were treated with a combination of 
vasoactive drugs and a single injection of cyanoacrylate.  After achieving homeostasis, 
follow-up was conducted on day 6 and continued thereafter.  The primary outcomes 
were gastric variceal rebleed and death.  Secondary outcomes included an increase or 
decrease in size of the gastric varices, appearance of new esophageal varices, and 
appearance or worsening of portal hypertensive gastropathy (PHG) and complications.11 
Patients with gastroesphageal varices type 2 with eradicated esophageal varices 
or isolated gastric varices type 1 who bled from gastric varices who did not satisfy the 
exclusion criteria were included in the study.  Patients were randomized using a sealed 
envelope technique.  Allocation sequence remained known to the statistician.  
Investigators were blinded until intervention was assigned.  Blinding was further 
achieved by concealing the group assignment from the doctors who evaluated the 
outcomes. 11   
The study consisted of 64 patients, 32 patients received cyanoacrylate injection 
and 32 received the non-selective beta-blocker, propranolol.  Both groups were similar 
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in all baseline patient characteristics.  All patients completed their assigned intervention 
with a median follow-up period of 26 months.  Complete obturation with cyanoacrylate 
was achieved in all patients.  All patients were compliant to the beta-blocker treatment 
with a mean dose of 160 mg per day.11 
Treatment with cyanoacrylate demonstrated a significantly lower rate of 
recurrent variceal bleeding compared to beta-blocker treatment (15% compared to 
55%, p=0.004).  Three patients rebled in the cyanoacrylate treatment group (GOV2 
(n=1), IGV1 (n=2)).  Fifteen patients rebled in the beta-blocker group (GOV2 (n=12), IGV1 
(n=3)).  The study also showed a significant increase in frequency of rebleeding from 
GOV2 (p=0.005).  A decrease in gastric variceal size from ~25 to ~5 mm was observed in 
all patients receiving cyanoacrylate injection (p<0.01).  In contrast, 15 patients in the 
beta-blocker group had an increase in gastric variceal size ~25 to ~30 mm (p<0.01).  
Seven patients in the cyanoacrylate group and four patients in the beta-blocker group 
developed esophageal varices, none of which bled (p=0.302).  Both treatment groups 
were similar in appearance or worsening of PHG (p=0.213).  There was no significant 
difference in frequency of complication observed between the two groups (p=1).  A 
significant increase in hepatic venous pressure gradient (HVPG) was observed in the 
cyanoacrylate group (p=0.001).  None of the patients in the cyanoacrylate group showed 
a decrease in HVPG.  The beta-blocker group demonstrated a decrease in HVPG, which 
was significant (p=0.003).  A >20% reduction in HVPG was considered a response to 
treatment.  Twelve patients responded to treatment.  Five of those patients (GOV2 
(n=4), IVG1 (n=1)) bled.  Those who did not bleed had a mean decrease in HVPG of 30% 
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from baseline in comparison with a 22% decrease in those who bled.  A significant 
difference in mortality was observed between the cyanoacrylate (n=1) and beta-blocker 
(n=8) group (p=0.016).  Of the eight who died in the beta-blocker group, one patient 
responded to the beta-blocker treatment while the other patients did not (p=0.077).11 
The authors found that a limitation to this study is including only patients with 
IGV1 or GOV2 types of gastric varices.  This limits the applicability of the study to those 
two types of gastric varices.  The authors conclude that cyanoacrylate is more effective 
in preventing secondary gastric variceal rebleeds and improve survival rates compared 
to beta-blocker treatment.  Beta-blockers did not prevent gastric variceal rebleed 
despite a reduction in HVPG.11 
 
Evrard et al study 
In this randomized trial,13 the authors investigated whether Histoacryl injections 
are useful for long-term treatment of esophageal varices.  They compared Histoacryl 
obliteration with propranolol in preventing esophagogastric variceal rebleeds.  From 
August 1995 to February 1999, seventy-one patients were admitted for upper digestive 
tract bleeding.  Forty-one patients who presented with the first episode of bleeding 
(n=38) or second episode occurring at least 6 months after the first one (n=3) satisfied 
the inclusion criteria and were enrolled in the study.    Thirty-one patients presented 
with esophageal varices and 10 patients had gastric varices.  All patients were treated 
with Histoacryl at the time of admission to achieve hemostasis.  An opaque sealed 
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envelope was used to randomly assign patients to either the Histoacryl (n=21) or 
propranolol group (n=20).13 
The primary endpoints were rate of rebleeds, mortality and any complications, 
which were investigated at 6 weeks and after 6 weeks (the median follow-up duration of 
the Histoacryl group was 31.9 months and 23.2 months for the beta-blocker group).  The 
authors agreed that the 6-week mark is an important time point for follow-up.  They 
believed that this time point is when all consequences related to the bleeding event will 
manifest themselves.  The authors performed an interim analysis after observing a 
higher complication rate in the Histoacryl group.  The study was stopped early based on 
the results of the analysis.13   
The data demonstrated no significant difference in rate of rebleeds at the 6-
week mark.  Five patients from the Histoacryl group rebled, 3 of which were gastric 
variceal rebleeds.  Three patients in the beta-blocker group developed secondary 
variceal rebleeds, none of which were gastric in origin.  Three patients died from the 
Histoacryl group compared to six in the beta-blocker group.  Both groups had one 
patient who died from hemorrhage.   
Median follow-up after 6-weeks for the Histoacryl group was 31.9 months (4.8-
74.7) in contrast to the beta-blocker group which had a median follow-up of 23.2 
months (3.0-70).  No significant difference in rebleeds was observed between the two 
treatment groups.  Six patients from the Histoacryl group experienced rebleeds, two 
that were secondary to gastric varices.  Two patients in the beta-blocker group 
developed rebleeds, none located in the gastric region.  The investigators did find that 
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the time between rebleeds was significantly delayed in the Histoacryl group.  It was also 
observed that most of the patients who developed rebleeds in the Histoacryl group did 
not adhere to the recommended endoscopic follow-up schedule.  No significant 
difference was observed in the overall mortality rate.  One patient in the Histoacryl 
group died from hemorrhage in contrast to the beta-blocker group, which had no 
patient death from hemorrhage.  Data analysis demonstrated a significantly higher 
incidence of complications in the Histoacryl group (n=10) compared to the beta-blocker 
group (n=2) (p<0.02).  Most of the complications in the Histoacryl group occurred after 
esophageal injection (n=8).13   
Evrard et al13 concluded that the use of Histoacryl injection with the goal of 
eradicating esophagogastric varices were associated with more complications compared 
to beta-blocker treatment.  They also determined that there were no significant 
differences in rate of rebleeds and long-term survival rates between the two groups.  
The authors speculated that the higher number of rebleeds in the Histoacryl group 
maybe related to non-adherence to the follow-up schedule.  They also mentioned that 
the complications in the Histoacryl group were temporary and inconsequential, and 
severe complications such as embolism are infrequent.  An interesting observation from 
the study was that all the rebleeds from gastric varices occurred in the Histoacryl group.  
The study was stopped early after results of an interim analysis. 13 
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DISCUSSION 
It has been reported that gastric varices occur in over 20% of patients with portal 
hypertension.1 2  They are often present in patients with severe portal hypertension 
secondary to cirrhosis.  Gastric varices are also associated with a higher rate of rebleeds 
after homeostasis.3 5 6 Both studies11,13 have differing conclusions on the efficacy of 
cyanoacrylate and beta-blocker treatment in the prophylaxis of secondary gastric 
variceal hemorrhage.  The Mirshra study11 demonstrated that cyanoacrylate maybe 
effective in preventing secondary gastric varices.  The study included a multivariate 
analysis with variables that affect gastric variceal rebleeds.  The analysis indicated that 
the treatment method, portal hypertensive gastropathy and size of gastric varix >20 mm 
independently correlated with gastric variceal rebleeds.  Specifically, the cyanoacrylate 
group saw a decrease in varix size compared to the beta-blocker group, which saw an 
average increase in gastric variceal size of at least 5mm.11  This is a noteworthy finding as 
it may lead to changes in current standards and guidelines.  There was a also correlation 
with rebleeds and mortality in that only one patient in the cyanoacryte group died 
compared to eight patients in the beta-blocker group.  We may need to reevaluate the 
efficacy of emipiric beta-blocker treatment.  Moreover, the study also showed a 
significant increase in HVPG in the cyanoacrylate group.  The occlusion of the bleeding 
varice redirects the flow of blood to other vessels.  This could explain the increase 
incidence of esophageal varices seen in this group compared to the beta-blocker group.   
In contrast, the study conducted by Evrard et al13 demonstrated inconclusive 
results in regards to gastric rebleeding, but they do reaffirm the efficacy of 
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cyanoacrylate in controlling acute hemorrhage of gastric varices.  They found no 
difference in rate of rebleeds and mortality between the two groups.  The authors found 
that rebleeding from the Histoacryl group were from gastric varices.  This observation 
may support the use of beta-blockers in the prevention of secondary gastric varices and 
should be further investigated.13 
Both studies11,13 have limitations and their findings need further investigation to 
fully understand the benefits of the two treatment options in gastric variceal therapy.  
The Mirshra study11 was limited because small sample size and some lack of blinding.  
Since the comparison was between a procedure (cyanacylate injection) and an oral 
medication (propanolol), allocation concealment is inheritantly difficult.  No mention of 
a double dummy technique was used.  This study also did not use hemodynamic 
monitoring in measuring HVGP.  The HVGP is estimated by measuring the pressure 
gradient between the wedged hepatic venous pressure and the free hepatic venous 
pressure.  This study only included patients with either GOV2 or IVG2 varices.  This may 
limit the application to those types of varices in the clinical setting. 
The Evrard et al study13 was even more limited in a number of aspects.  The 
authors observed a high rate of complications in the Histoacryl group and performed an 
interim analysis.  The study was terminated prematurely based on the results; this lead 
to a small sample size in the study.  The complication mostly occurred in patients with 
esophageal varices who were treated with Histoacryl.  This may limit the applicability of 
the study to those with esophageal varices.  The authors observed an increasing rate of 
rebleeds long-term in the Histoacryl group.  However, no definitive conclusions can be 
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made due to the small sample size.  Patient compliance was another issue in this study 
since many patients didn’t follow the scheduled endoscopic appointments, which may 
have influenced the rate of rebleeds in the Histoacryl group.  Another possible 
explanation of the increase in complication is the use of lipiodol.  As we know, mixing 
lipiodol with cyanoacrylate will delay the solidification, which can lead to complications 
such as distant embolism.  This study13 did not clarify which type of gastric varices 
included in the study.  As mentioned earlier, the location of the gastric varices plays a 
role in the frequency of rebleeds and severity of bleeding.5  This study can be strengthen 
by including more patient and clearly defining the type of gastric varices. 
The GRADE quality assessment can be viewed on Table 1.  The Mirsha et al 
study11 was downgraded for the lack of patient blinding.  Serious imprecision was also 
determined from the study.  There was a small sample size, which weakens the study.  
Indirectness and inconsistency were not serious and no publication bias was observed in 
the study.  This article was not upgraded.  The overall quality for this article is low.  After 
review, it was determined that the Evrard et al study13 demonstrated serious 
limitations, indirectness and imprecision.  The study had a small sample size and a lack 
of patient blinding.  The primary outcome was not gastric rebleeding and the study was 
downgraded.  The inconsistency of the study was not serious and no publication bias 
was determined.  No upgrade was given.  Based on the GRADE criteria, the overall 
quality for this article was very low.  The overall combined quality of the studies 
reviewed is low based on the GRADE criteria 
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CONCLUSION 
The Mirshra et al11 study demonstrates that cyanoacrylate alone may be 
effective in preventing secondary gastric varice bleedings while the Evrard et al13 study 
is inconclusive.  More specifically, the evidence supports its use with patients with 
gastroesophageal varices type 2 and isolated gastric varices type 1.  The benefit of this 
treatment may outweigh the risk of rare complications like cyanoacrylate embolism.  
Currently, cyanoacrylate is not considered first-line treatment in the United States for 
gastric varice hemorrhage.  Based on the findings, cyanoacrylate should be considered 
and recommended when treating acute gastric hemorrhage.  Due to the limitations of 
the article, we can only speculate the benefits of cyanoacrylate in the prevention of 
secondary gastric variceal hemorrhage.  Further research with larger sample size is 
needed to fully understand the effectiveness of cyanoacrylate in the prevention of 
secondary gastric variceal rebleeds.  Another interesting avenue of research is to 
compare the efficacy of cyanoacrylate alone or mixed with lipiodol. 
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Table I. Characteristics of Reviewed Studies 
































a lack of blinding 
b primary outcome was not gastric rebleeding 











Quality Assessment  
 Downgrade Criteria Quality 
Design Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely  
Mirshra et al Study11  
RCT 
 Serious







Evrard et al Study13  






 Number of Patients Outcomes 
Study Treatment (total) 
Placebo or no 
treatment 
(total) 
Rebleeds Mortality Complications   
Mirshra et al11 33 34 3 1 1   
Evrard et al13 18 14 2 2 3   
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Figure I. Sarin Classification System 
 
 
 
